David A. Scheinberg

Affiliations: 
Weill Cornell Medical College, New York, NY, United States 
Area:
Biochemistry
Google:
"David Scheinberg"
Mean distance: (not calculated yet)
 
BETA: Related publications

Publications

You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Oh CY, Klatt MG, Bourne C, et al. (2019) ALK and RET inhibitors promote HLA class I antigen presentation and unmask new antigens within the tumor immunopeptidome. Cancer Immunology Research
Dao T, Mun SS, Scott AC, et al. (2019) Depleting T regulatory cells by targeting intracellular Foxp3 with a TCR mimic antibody. Oncoimmunology. 8: 1570778
Gejman RS, Chang AY, Jones HF, et al. (2018) Rejection of immunogenic tumor clones is limited by clonal fraction. Elife. 7
Mondello P, Brea EJ, De Stanchina E, et al. (2018) Panobinostat acts synergistically with ibrutinib in diffuse large B cell lymphoma cells with MyD88 L265 mutations. Jci Insight. 3
Mulvey JJ, Littmann ER, Ling L, et al. (2018) The effects of amine-modified single-walled carbon nanotubes on the mouse microbiota. International Journal of Nanomedicine. 13: 5275-5286
Maslak PG, Dao T, Bernal Y, et al. (2018) Phase 2 trial of a multivalent WT1 peptide vaccine (galinpepimut-S) in acute myeloid leukemia. Blood Advances. 2: 224-234
Zauderer MG, Tsao AS, Dao T, et al. (2017) A Randomized Phase II Trial of Adjuvant Galinpepimut-S, WT-1 Analog Peptide Vaccine, after Multimodality Therapy for Patients with Malignant Pleural Mesothelioma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research
Chang AY, Dao T, Gejman RS, et al. (2017) A therapeutic T cell receptor mimic antibody targets tumor-associated PRAME peptide/HLA-I antigens. The Journal of Clinical Investigation. 127: 3557
Alidori S, Thorek DLJ, Beattie BJ, et al. (2017) Carbon nanotubes exhibit fibrillar pharmacology in primates. Plos One. 12: e0183902
Chang AY, Dao T, Gejman RS, et al. (2017) A therapeutic T cell receptor mimic antibody targets tumor-associated PRAME peptide/HLA-I antigens. The Journal of Clinical Investigation
See more...